Resigratinib - XOMA
Alternative Names: KIN-3248Latest Information Update: 17 Jul 2026
At a glance
- Originator Kinnate Biopharma
- Class Alkenes; Alkynes; Amides; Amines; Antineoplastics; Benzimidazoles; Cyclopropanes; Ethers; Fluorocarbons; Pyrazoles; Pyrrolidines; Small molecules
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cholangiocarcinoma; Solid tumours; Urogenital cancer